Juvaris BioTherapeutics Initiates Phase 1 Clinical Trial Of JVRS-100 Adjuvanted Seasonal Influenza Vaccine

Juvaris BioTherapeutics, Inc., a biotechnology company developing therapeutics and adjuvanted vaccines for infectious diseases and cancer, announced the initiation of a Phase 1 clinical trial of its lead compound, JVRS-100. The trial will compare the safety, tolerability and immunogenicity of the JVRS-100 adjuvant co-administered with a commercial influenza vaccine compared to vaccine alone.

More: continued here

Filed under: Flu / SARS on June 1st, 2008